.png)
TL;DROriginator medicine (Originalpräparat), in EU law the reference medicinal product (Referenzarzneimittel), is the first product with a given active substance to receive a marketing authorisation, granted on the strength of its own complete clinical dossier. Every later generic and every biosimilar of that substance derives from it and refers back to its data.
Under Article 8(3) of Directive 2001/83/EC the originator is authorised on a full dossier: the results of pharmaceutical tests, of preclinical pharmacological and toxicological tests, and of clinical trials. This is the expensive route, and it is the counterpart to the abridged generic route of Article 10, which exists precisely so that later products do not have to repeat it. In return the originator earns two kinds of protection, and they are frequently confused.
The term originator (Originalpräparat) is used loosely in day-to-day language for any branded first product, but in a regulatory sense it is the reference medicinal product: the specific authorisation on whose dossier a later generic or biosimilar is allowed to rely. That is a precise legal status, not a marketing description, and it is the reason the same product can be described interchangeably as originator, Referenzarzneimittel or Erstanbieterpräparat.
The originator carries the full evidentiary burden and the full protection, and the generic references both. The table sets out the contrast.
| Aspect | Originator medicine (Originalpräparat) | Generic |
|---|---|---|
| Authorisation basis | Full dossier, Article 8(3) | Abridged application, Article 10 |
| Clinical evidence | Own preclinical and clinical trials | Bioequivalence with the originator |
| Role | Reference medicine for generics and biosimilars | Copy referring to the reference dossier |
| Protection | Patents plus 8+2(+1) data and market exclusivity | None of its own as a copy |
| Price over time | Higher while protected, eroded after expiry | Enters below the originator, drives the price down |
These are two separate protections with different owners, different legal bases and different clocks, and conflating them is the most common error in market-access planning. A patent is an intellectual property right that protects the invention, for example the molecule or a specific use. It is granted by patent offices, runs about twenty years from filing, and can be extended by a supplementary protection certificate to offset development time. Data and market exclusivity is a regulatory protection that comes automatically with the marketing authorisation, is independent of patent status, and cannot be extended by a patent instrument. Either one can be the barrier that actually delays a generic, and both must be clear before a generic can be sold.
The regulatory clock, verified against the EMA, runs in a fixed sequence.
This is the 8+2(+1) framework. Note that it protects the dossier, not the molecule: patents can run longer or shorter, and it is whichever protection expires last that opens the market.
Patent expiry, or the end of exclusivity, is the moment the originator's market changes shape. Generic manufacturers enter with bioequivalent copies at lower prices, and the originator faces rapid price erosion as substitution and reference pricing take effect. In practical terms the originator usually loses its place among the cheapest products in its group, which is the position that matters for German substitution and reimbursement. The vier-günstigste-Regel entry explains why that specific ranking is decisive. For the manufacturer this is the well-documented patent cliff: revenue that depended on a protected price can fall sharply within months of the first generic launch, which is why loss-of-exclusivity dates drive so much market-access and portfolio planning.
The originator also keeps a second role after expiry. It remains the reference against which the equivalence of new products is judged: bioequivalence for a generic, and the comparability exercise for a biosimilar, where the originator is the biological reference medicine. The biosimilar entry sets out that second pathway.
In the tabular article master data view the originator status is carried as a compact flag, and the links to the products that derive from it sit in the article comparison block, drawn from the licensed ABDA article master data.
One honest limitation: the OP flag identifies a product as an originator, but it does not tell you the remaining patent or exclusivity term. Patent and supplementary-protection status is litigated product by product and held in specialist legal registers, not in the article master data, so the flag places a product in the market structure without dating the end of its protection.
